|
Cascales Campos P, Martinez Insfran LA, Wallace D, Gil J, Gil E, Gonzalez Gil A, Martinez J, Alonso Romero JL, Gonzalez Sanchez R, Parrilla P. Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy. Clin Transl Oncol. 2020 Jun;22(6):852-859. doi: 10.1007/s12094-019-02195-8. Epub 2019 Aug 7. PubMed PMID: 31392644.
AÑO: 2020; IF: 3.405
|
|
Gonzalez-Santiago S, Saura C, Ciruelos E, Alonso JL, de la Morena P, Santisteban Eslava M, Gallegos Sancho MI, de Luna A, Dalmau E, Servitja S, Ruiz Borrego M, Chacon JI. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study). Breast Cancer Res Treat. 2020 Nov;184(2):469-479. doi: 10.1007/s10549-020-05866-1. Epub 2020 Sep 2. PubMed PMID: 32876911.
AÑO: 2020; IF: 4.872
|
|
Ros-Martinez S, Navas-Carrillo D, Alonso-Romero JL, Orenes-Pinero E. Immunoscore: a novel prognostic tool. Association with clinical outcome, response to treatment and survival in several malignancies. Crit Rev Clin Lab Sci. 2020 Nov;57(7):432-443. doi: 10.1080/10408363.2020.1729692. Epub 2020 Mar 16. PubMed PMID: 32175789.
AÑO: 2020; IF: 6.25
|
|
Perez-Garcia, JM; Llombart-Cussac, A; Holgado, E; Curigliano, G; Miranda, EL; Alonso-Romero, JL; Bermejo, B; Calvo, L; Caranana, V; Sanchez, SD; Cortes, MG; Vazquez, RM; Prat, A; Borrego, MR; Sampayo, M; Segui, MA; Soberino, J; Malfettone, A; Schmid, P; Cortes, J. A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study). CANCER RESEARCH. 2020; 80(4). 10.1158/1538-7445.SABCS19-P3-09-03
AÑO: 2020; IF: 12.701
|
|
Todo, FR; Stradella, A; Garcia-Saenz, JA; De Las Heras, BB; Romero, JLA; Barnadas, A; Peron, YI; Alba, E; Lopez-Tarruella, S; Henao-Carrasco, F; Carrasco, E; Caballero, R; Del Campo, M. Unraveling trastuzumab emtansine resistance in HER2-positive advanced breast cancer: GEICAM KATIA study. ANNALS OF ONCOLOGY. 2020; 31:S391-S391. 10.1016/j.annonc.2020.08.456
AÑO: 2020; IF: 32.976
|